X4 Pharma's 30-to-1 Reverse Split: Racing Against Nasdaq Clock While Phase 4WARD Trial Progresses

X4 Pharmaceuticals (XFOR) faces a critical juncture as it executes a 1-for-30 reverse stock split set for April 28, 2025, a move designed to stabilize its listing status on the Nasdaq Capital Market. The pharmaceutical company disclosed this decision after its board authorized the consolidation strategy, which will compress approximately 173.6 million outstanding shares into roughly 5.8 million shares post-split.

Why the 30-to-1 Consolidation Matters

The reverse split addresses a pressing compliance issue: maintaining minimum bid price requirements mandated by Nasdaq. Back in August 2024, X4 received a deficiency notice signaling the company had fallen below the $1.00 per share threshold. The deadline extension granted by the exchange runs through August 11, 2025, giving the company a narrow window to demonstrate compliance and preserve its market position.

At current trading levels around $0.18 per share (down 8.64% recently on Nasdaq), the company’s stock reflects sector headwinds and investor sentiment. The consolidation mechanism effectively combines every 30 shares into a single share, theoretically elevating the post-split price proportionally if trading volumes remain steady.

Shareholder and Security Adjustments

Fractional share holders won’t be left hanging—they’ll receive cash compensation instead. Meanwhile, the split will cascade through X4’s capital structure, triggering proportional recalibrations to equity grants, stock options, and warrant positions. The Class C warrants maintain their existing CUSIP designation, though trading will migrate to the new identifier 98420X202 starting April 28.

Pipeline Progress Amid Market Pressure

Despite stock price pressures, X4 continues advancing its clinical agenda. The company markets XOLREMDI, its CXCR4 antagonist therapy, while simultaneously progressing its Phase 3 4WARD trial targeting chronic neutropenia—a 30-day and beyond duration study designed to validate long-term safety and efficacy profiles.

The reverse split represents a defensive maneuver, but X4’s ability to maintain Nasdaq listing ultimately depends on whether pipeline progress translates into revenue momentum and investor re-engagement post-consolidation.